PRECISE-DAPT Score Research Articles

The association of PRECISE-DAPT score with development of contrast-induced nephropathy in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Given that parameters used in the calculation of the PRECISE-DAPT risk score are important contributors to contrast-induced nephropathy (CIN) development, we hypothesized that the PRECISE-DAPT risk score would show good accuracy for predicting CIN in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Therefore, in this study, we aimed to determine the predictive value of the admission PRECISE-DAPT score for the occurrence of CIN in patients with STEMI treated with primary PCI. After evaluation regarding with exclusion criteria, 1280 patients were, respectively, enrolled in the study. The primary end-point was the incidence of CIN. The PRECISE-DAPT score of CIN group was higher than the non-CIN group [31 (24-41) vs. 14 (9-23), p < 0.001, respectively]. In multivariate logistic regression analysis, PRECISE-DAPT score was independently associated with the development of CIN [odds ratio (OR) 1.090, 95% confidence interval (CI) 1.066-1.114, p < 0.001]. A receiver-operating characteristic (ROC) analysis was drawn to show the best cut-off value of the PRECISE-DAPT score to predict CIN was ≥ 21 with 81.3% sensitivity and 72.7% specificity [area under curve (AUC): 0.834; 95% CI 0.812-0.854; p = 0.017]. The PRECISE-DAPT score may be a significant independent predictor of CIN in patients with STEMI treated with primary PCI. Therefore, follow-up of patients with higher PRECISE-DAPT score should be performed more cautiously, and it should be noted that the development of CIN risk of these patients group is high.

Correlations of DAPT score and PRECISE-DAPT score with the extent of coronary stenosis in acute coronary syndrome.

Dual antiplatelet therapy (DAPT) score and PRECISE-DAPT score were recommended for decision making of optimal DAPT in discriminating the risk of thrombosis and bleeding. But the relationships between 2 scoring tools with the extent of coronary stenosis have not been established.We retrospectively enrolled 359 patients of acute coronary syndrome (ACS) who received percutaneous coronary intervention. Both DAPT score and PRECISE-DAPT score were calculated, and patients were divided by their recommended cut-offs. Gensini score and triple-vessel disease (3-VD) were chosen to evaluate the severity of coronary stenosis.Overall, 54.9% and 10.0% of the patients had higher DAPT score (≥2) or PRECISE-DAPT score (≥25). Patients with higher DAPT score had increased stent counts, total length of stents, Gensini score, and proportion of 3-VD, but decreased minimum diameter of stent. But these differences were not found in PRECISE-DAPT subgroups. When divided into quartiles of both scoring systems, the highest Gensini score and proportions of 3-VD were found in the fourth quartile of both DAPT score and PRECISE-DAPT score. Moreover, both DAPT score and PRECISE-DAPT score were independent risk factors of Gensini score after adjustment (P < .001 and P = .047). Furthermore, an increase of 1 point of DAPT score and 5 points of PRECISE-DAPT score resulted by 51% (odds ratios [OR]: 1.51, 95% confidence interval [CI]:1.19–1.91, P = .001) and 34% (OR: 1.34, 95% CI: 1.11–1.62, P = .003) increase in risk of 3-VD after adjustment.Both DAPT score and PRECISE-DAPT score were independently associated with the degree of coronary stenosis in patients with ACS.

TCT-854 The PRECISE-DAPT score: relationship with clinical outcomes after drug-eluting stents implantation and with thrombotic-ischemic scores

The consideration of bleeding risk is of paramount importance for tailoring dual antiplatelet therapy (DAPT) duration. In this regard the recently released focused update on DAPT of the European Society of Cardiology includes the recommendation to use the PRECISE DAPT score to estimate the risk of

TCT-541 The validity of PRECISE-DAPT score for the predicting bleeding complication in patients treated with dual antiplatelet therapy

Dual antiplatelet therapy prevents ischemic events after coronary stenting, but increases bleeding. Several risk scores have been proposed for the management of patients treated with DAPT, but no standardized tool exists for this purpose. We sought to assess the performance of CRUSADE, ACUITY and

P1720DAPT and PRECISE DAPT scores in identifying patients at high bleeding risk after percutaneous coronary intervention

P1720DAPT and PRECISE DAPT scores in identifying patients at high bleeding risk after percutaneous coronary intervention

P1717Patients eligible for prolonged dual antiplatelet treatment one year after acute coronary syndrome according to the of PRECISE-DAPT score and DAPT score

P1717Patients eligible for prolonged dual antiplatelet treatment one year after acute coronary syndrome according to the of PRECISE-DAPT score and DAPT score

P3179Exploring the value of the PRECISE-DAPT score after complex percutaneous coronary intervention to inform dual antiplatelet therapy duration decision-making

P3179Exploring the value of the PRECISE-DAPT score after complex percutaneous coronary intervention to inform dual antiplatelet therapy duration decision-making

P5558Comparative evaluation of the predictive capacity of post-discharge bleeding PRECISE-DAPT score among patients discharged with ticagrelor or prasugrel vs. clopidogrel in ACS patients treated with DES

P5558Comparative evaluation of the predictive capacity of post-discharge bleeding PRECISE-DAPT score among patients discharged with ticagrelor or prasugrel vs. clopidogrel in ACS patients treated with DES

P612Usefulness of combined SYNTAX and PRECISE-DAPT score for predicting major bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention

P612Usefulness of combined SYNTAX and PRECISE-DAPT score for predicting major bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention

1399Accuracy of the PRECISE-DAPT score vs. CRUSADE score for in-hospital and post-discharge bleeding prediction in patients with acute coronary syndrome

1399Accuracy of the PRECISE-DAPT score vs. CRUSADE score for in-hospital and post-discharge bleeding prediction in patients with acute coronary syndrome

Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry

IntroductionTicagrelor and prasugrel are recommended as first line therapy in patients with acute coronary syndromes (ACS). However, patients with anemia are commonly treated with clopidogrel in routine clinical practice. The RENAMI registry (REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction) included ACS patients treated with prasugrel or ticagrelor at hospital discharge. The aim of this study was to analyze the prevalence of anemia and characteristics and outcomes of these patients according to anemia status. MethodsConsecutive patients with ACS from 11 centers were included. All patients underwent percutaneous coronary intervention (PCI). Anemia was defined as hemoglobin <130 g/L in men and <120 g/L in women. The incidence of ischemic and bleeding events and all-cause mortality were assessed at one year. ResultsFrom 4424 patients included, 405 (9.2%) fulfilled criteria of anemia. Patients with anemia were significantly older, had a higher prevalence of peripheral artery disease, previous bleeding and renal disfunction and higher bleeding risk (PRECISE-DAPT score ≥ 25: 37.3% vs 18.8%, p < 0.001) The incidence of BARC 3/5 bleeding was moderately higher in patients with anemia (5.4% vs 1.5%, p = 0.001). The incidence of stent thrombosis or reinfarction was not significantly different according to anemia status. Anemia was independently associated with mortality (HR 1.73; 95% CI 1.03-2.91, p = 0.022). ConclusionsA not negligible proportion of patients treated with ticagrelor or prasugrel met criteria for anemia. Anemia was an independent predictor of mortality. Despite their higher bleeding risk profile, patients with anemia had an acceptable rate of bleeding.

VALIDATION OF THE PREDICTING BLEEDING COMPLICATIONS IN PATIENTS UNDERGOING STENT IMPLANTATION AND SUBSEQUENT DUAL ANTIPLATELET THERAPY (PRECISE-DAPT) SCORE IN THE ELDERLY POPULATION

The PRECISE-DAPT score has been recently developed as an attractive tool for the prediction of bleeding after percutaneous coronary intervention (PCI). Our aim was to assess the performance of this score specifically in the elderly population. We calculated the PRECISE-DAPT score (age, creatinine

CLINICAL USEFULNESS OF PRECISE DAPT SCORE TO PREDICT CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH STENTING

Oral anticoagulant therapy (OAC) with dual antiplatelet therapy (DAPT) increases the risk of hemorrhagic complications in patients with AF undergoing percutaneous coronary intervention (PCI) with stenting. The PRECISE-DAPT score is a simple five-item prediction algorithm for the prediction of out-of

In patients receiving DAPT after coronary stents, the PRECISE-DAPT score predicted bleeding moderately well.

Source Citation Costa F, van Klaveren D, James S, et al; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantati...

Tailoring Dual Antiplatelet Therapy after Coronary Stenting: The PRECISE-DAPT Score versus the DAPT Score

Tailoring Dual Antiplatelet Therapy after Coronary Stenting: The PRECISE-DAPT Score versus the DAPT Score

Repetitive Assessement of PRECISE-DAPT Score

Repetitive Assessement of PRECISE-DAPT Score